AstraZeneca will co-develop stem cell drugs for diabetic blindness

09/12/2010 | Guardian (London), The

AstraZeneca signed a three-year research agreement with the University College London's Institute of Ophthalmology to discover and develop stem-cell-based drugs to treat diabetic retinopathy. "We're getting very keen on the whole area of regenerative medicines, and they will be part of our research development over the next few years," an AstraZeneca official said.

View Full Article in:

Guardian (London), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Sr. Compliance Director Ethics and Compliance
Medtronic
Fridley, MN
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC